SK Pharmteco, a subsidiary of SK Group, is reportedly contemplating the sale of its pharmaceutical manufacturing plant in Virginia to Novo Nordisk, a Danish pharmaceutical company. The plant, located in Petersburg, Virginia, spans over 600,000 square meters and has a production capacity of 188 cubic meters. SK Pharmteco acquired the facility in 2018 for approximately 800 billion won, but it is now rumored to be in talks to sell it to Novo Nordisk for around 300 billion won, significantly less than the initial acquisition price. Despite these reports, an SK Pharmteco official has denied the existence of any ongoing discussions for the sale of the plant to Novo Nordisk, stating that while they are open to various options, there are no specific plans to dispose of the site to any particular buyer at the moment. The potential sale comes at a time when Novo Nordisk is aiming to expand its production capacity to meet the increasing demand for its weight-loss drug, Wegovy. This expansion includes the construction of a new fill-finish plant in North Carolina and the acquisition of Catalent, a New Jersey-based pharmaceutical company, to bolster the supply of Wegovy. Industry sources suggest that Novo Nordisk's interest in SK Pharmteco's Virginia plant is driven by the need to enhance its manufacturing capacity for Wegovy and Ozempic, a blood sugar modulating treatment. However, it is unclear whether the speculated deal will materialize at the reported 300 billion won value.